The global artificial heart-lung machine market reached a value of US$ 319.3 Million in 2020. Looking forward, the publisher expects the market to grow at a CAGR of 6.2% during 2021-2026. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
An artificial heart-lung machine, also known as a cardiopulmonary bypass (CPB) or oxygenator pump, is used during coronary artery bypass, heart and lung transplants, and other cardiac surgeries. It temporarily performs the functions of the heart and lungs to enable the surgeon to operate in motion and bloodless surgical field. These machines consist of a chamber that receives blood, which is then oxygenated and circulated to all body parts. Over the years, these pumps have helped in making significant advances in the management of severe respiratory failure as well as in the field of car-diac surgeries.
In recent years, there has been a significant rise in the number of open-heart surgeries, heart transplants and lung surgeries across the globe. This can primarily be attributed to various environmental and lifestyle changes, which have led to an increase in the prevalence of cardiovascular diseases and the instances of organ failures. Other than this, governments of several developing nations are making efforts for providing improved healthcare facilities to patients, which is driving the demand for artificial heart-lung machines. Furthermore, the market players are investing in research and development activities to modernize the current models of oxygenator pumps. These activities have led to the development of modular heart-lung machines that are cost-effective, safe, and user-friendly in nature. Besides this, these machines also offer flexibility to doctors as they are portable and can be operated on rechargeable batteries. The manufacturers have also made several improvements in CPB pumps to prevent the over-oxygenation of blood.
An artificial heart-lung machine, also known as a cardiopulmonary bypass (CPB) or oxygenator pump, is used during coronary artery bypass, heart and lung transplants, and other cardiac surgeries. It temporarily performs the functions of the heart and lungs to enable the surgeon to operate in motion and bloodless surgical field. These machines consist of a chamber that receives blood, which is then oxygenated and circulated to all body parts. Over the years, these pumps have helped in making significant advances in the management of severe respiratory failure as well as in the field of car-diac surgeries.
In recent years, there has been a significant rise in the number of open-heart surgeries, heart transplants and lung surgeries across the globe. This can primarily be attributed to various environmental and lifestyle changes, which have led to an increase in the prevalence of cardiovascular diseases and the instances of organ failures. Other than this, governments of several developing nations are making efforts for providing improved healthcare facilities to patients, which is driving the demand for artificial heart-lung machines. Furthermore, the market players are investing in research and development activities to modernize the current models of oxygenator pumps. These activities have led to the development of modular heart-lung machines that are cost-effective, safe, and user-friendly in nature. Besides this, these machines also offer flexibility to doctors as they are portable and can be operated on rechargeable batteries. The manufacturers have also made several improvements in CPB pumps to prevent the over-oxygenation of blood.
Report Coverage:
- Historical, Current and Future Market Trends
Market Breakup by Type:
- Single Roller Pump
- Double Roller Pump
Market Breakup by Application:
- Cardiac Surgeries
- Lung Surgeries
- Acute Respiratory Failure Treatment
- Others
Market Breakup by End User:
- Hospitals and Clinics
- Ambulatory Surgical Centers
- Others
Market Breakup by Region:
- North America
- Europe
- Asia Pacific
- Middle East and Africa
- Latin America
Competitive Landscape:
The report has also analysed the competitive landscape of the market with some of the key players being Medtronic Inc, Sorin Group, MAQUET GmbH & Co. KG, Terumo Corporation, C.R. Bard Inc, Tianjin Medical, Edwards Lifesciences, Jarvik Heart, Braile Biomédica, SynCardia, etc.Key Questions Answered in This Report:
- How has the global artificial heart-lung machine market performed so far and how will it perform in the coming years?
- What are the key regional markets in the global artificial heart-lung machine industry?
- What has been the impact of COVID-19 on the global artificial heart-lung machine industry?
- What is the breakup of the market based on the type?
- What is the breakup of the market based on the application?
- What is the breakup of the market based on the end user?
- What are the various stages in the value chain of the global artificial heart-lung machine industry?
- What are the key driving factors and challenges in the global artificial heart-lung machine industry?
- What is the structure of the global artificial heart-lung machine industry and who are the key players?
- What is the degree of competition in the global artificial heart-lung machine industry?
Table of Contents
1 Preface3 Executive Summary11 Value Chain Analysis13 Price Analysis
2 Scope and Methodology
4 Introduction
5 Global Artificial Heart-Lung Machine Market
6 Market Breakup by Type
7 Market Breakup by Application
8 Market Breakup by End User
9 Market Breakup by Region
10 SWOT Analysis
12 Porter’s Five Forces Analysis
14 Competitive Landscape
List of Figures
List of Tables
Companies Mentioned
- Medtronic Inc
- Sorin Group
- MAQUET GmbH & Co. KG
- Terumo Corporation
- C.R. Bard Inc
- Tianjin Medical
- Edwards Lifesciences
- Jarvik Heart
- Braile Biomédica
- SynCardia
Methodology
LOADING...
